Under the guidance of Luc Gagnon, VP, Vaccine Sciences, the Nexelis head office and laboratory in Laval, Quebec, features more than 160 specialists in a state-of-the-art, 68,000 square foot BSL-2 site.
In addition, a new 1,500 sq. ft. BSL-3 laboratory will be opening late 2021 at Institut Armand Frappier. The new facility complements the existing BSL-2 facility utilized by Nexelis.
We have experience working with more than 60 vaccine manufacturers worldwide and are synonymous with leading vaccine development services. This expertise has made us the referral lab for prestigious governmental and nongovernmental institutions such as the Bill & Melinda Gates Foundation, CEPI, the U.K. Vaccine Task Force, BARDA, and more than 50 innovative biotechnology companies.
Through our partnership with Public Health England (PHE) Porton Down, we played a determinant role in the struggle against SARS-CoV-2 by developing reference vaccine and drug efficacy assessment assays. We are also a signatory of the World Health Organization’s (WHO) public statement for collaboration on SARS-CoV-2 vaccine development, and our assays have been transferred to laboratories all over the world through the Coalition for Epidemic Preparedness Innovations (CEPI) network.
Our laboratories operate according to GCLP standards and the preclinical in vivo unit managed by our partner Institut Armand Frappier is AAALAC, CCAC, and OLAW accredited.